AstraZeneca’s proposed treatment for heart disease delivered positive high-level results from the company’s Phase III DELIVER trial.
The 71st annual American College of Cardiology’s Scientific Session saw several wins – and some “mehs” led by some of biopharma’s largest companies, according to BioSpace.
Novartis’ Entresto is the first therapy approved in the United States to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF).
Cytokinetics’ stocks plummeted after the company released topline results from a Phase III cardiovascular clinical trial with partners Amgen and Servier in which the secondary endpoint to prove potential to save lives failed.
The U.S. Food and Drug Administration approved Farxiga (dapagliflozin) for the treatment of heart failure in adults with reduced ejection fraction.
New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s Farxiga (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure worsening or cardiovascular death compared to placebo, in patients with heart failure with reduced ejection fraction, irrespective of their background therapy.
Merck & Co. Inc.’s experimental treatment vericiguat being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.
AstraZeneca announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga (dapagliflozin) reduced the risk of the primary composite outcome of worsening heart failure or death from cardiovascular causes versus placebo, when added to standard of care.
